Evaluation of VZV-specific cell-mediated immunity in adults infected with HIV-1 by using a simple IFN-γ release assay
Copyright © 2013 Wiley Periodicals, Inc..
The development of herpes zoster is associated with reduced varicella zoster virus (VZV)-specific cell-mediated immune (CMI) reactions. In this study, VZV-specific CMI reactions in 42 anti-VZV-IgG antibody-positive adults infected with HIV-1 were evaluated by measuring the IFN-γ production levels in whole blood in response to stimulation with ultraviolet light-inactivated live attenuated VZV vaccine. The median VZV-specific IFN-γ production level in all patients was 63 pg/ml. Antiretroviral therapy (ART)-naïve patients with an AIDS-defining illness (HIV classification category C) had significantly lower IFN-γ production than ART-naïve patients in categories A and B and patients receiving ART (P=0.0194 and P=0.0046, respectively). IFN-γ production increased significantly in patients within 1 month of the onset of recurrent VZV disease and at more than 1 year from onset, compared with patients who had never had recurrent VZV disease (P=0.0396 and P=0.0484, respectively). In multivariate analyses, category C and history of recurrent VZV disease were significant factors affecting IFN-γ production. Levels of IFN-γ were measured before and after ART in seven ART-naïve patients with no history of recurrent VZV disease, and no significant changes were observed. The results indicate that VZV-specific CMI reactions were reduced in patients with an AIDS-defining illness and enhanced in patients with a history of recurrent VZV disease, but not enhanced by ART alone. Vaccination may be necessary to inhibit the development of herpes zoster in patients receiving ART; this IFN-γ releasing assay is one useful method for evaluating VZV-specific CMI reactions in clinical settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
Journal of medical virology - 85(2013), 8 vom: 21. Aug., Seite 1313-20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Watanabe, Dai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Retroviral Agents |
|---|
| Anmerkungen: |
Date Completed 23.12.2013 Date Revised 14.06.2013 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.23611 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM227756436 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM227756436 | ||
| 003 | DE-627 | ||
| 005 | 20231224074409.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.23611 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0759.xml |
| 035 | |a (DE-627)NLM227756436 | ||
| 035 | |a (NLM)23703688 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Watanabe, Dai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of VZV-specific cell-mediated immunity in adults infected with HIV-1 by using a simple IFN-γ release assay |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2013 | ||
| 500 | |a Date Revised 14.06.2013 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Wiley Periodicals, Inc. | ||
| 520 | |a The development of herpes zoster is associated with reduced varicella zoster virus (VZV)-specific cell-mediated immune (CMI) reactions. In this study, VZV-specific CMI reactions in 42 anti-VZV-IgG antibody-positive adults infected with HIV-1 were evaluated by measuring the IFN-γ production levels in whole blood in response to stimulation with ultraviolet light-inactivated live attenuated VZV vaccine. The median VZV-specific IFN-γ production level in all patients was 63 pg/ml. Antiretroviral therapy (ART)-naïve patients with an AIDS-defining illness (HIV classification category C) had significantly lower IFN-γ production than ART-naïve patients in categories A and B and patients receiving ART (P=0.0194 and P=0.0046, respectively). IFN-γ production increased significantly in patients within 1 month of the onset of recurrent VZV disease and at more than 1 year from onset, compared with patients who had never had recurrent VZV disease (P=0.0396 and P=0.0484, respectively). In multivariate analyses, category C and history of recurrent VZV disease were significant factors affecting IFN-γ production. Levels of IFN-γ were measured before and after ART in seven ART-naïve patients with no history of recurrent VZV disease, and no significant changes were observed. The results indicate that VZV-specific CMI reactions were reduced in patients with an AIDS-defining illness and enhanced in patients with a history of recurrent VZV disease, but not enhanced by ART alone. Vaccination may be necessary to inhibit the development of herpes zoster in patients receiving ART; this IFN-γ releasing assay is one useful method for evaluating VZV-specific CMI reactions in clinical settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Retroviral Agents |2 NLM | |
| 700 | 1 | |a Otani, Naruhito |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Sachiko |e verfasserin |4 aut | |
| 700 | 1 | |a Dohi, Hiromi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Kazuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yonemoto, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Otera, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yajima, Keishiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Yasuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Uehira, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Shima, Masayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shirasaka, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Okuno, Toshiomi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 85(2013), 8 vom: 21. Aug., Seite 1313-20 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2013 |g number:8 |g day:21 |g month:08 |g pages:1313-20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.23611 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2013 |e 8 |b 21 |c 08 |h 1313-20 | ||